Albert David Ltd
NSE: ALBERTDAVD BSE: 524075
₹709.10
(0.11%)
Sun, 24 May 2026, 00:56 pm
Market Cap4.17B
PE Ratio0
Dividend0.69
Health Technology
Pharmaceuticals: Major
24.5KAlbert David Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (8.7x coverage).
- Albert David's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Albert David's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Albert David is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Albert David is profitable, therefore cash runway is not a concern.
- Albert David is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (1748%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 99.1x debt.
- Albert David's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (30% vs 0.9% today).
- Albert David earns more interest than it pays, coverage of interest payments is not a concern.
- Albert David's level of debt (0.9%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Albert David board of directors is about average.
- More shares have been bought than sold by Albert David individual insiders in the past 3 months.
- Tarminder's remuneration is higher than average for companies of similar size in India.
misc
- Albert David is not covered by any analysts.
- Albert David has significant price volatility in the past 3 months.
past
- Albert David's 1-year earnings growth exceeds its 5-year average (66.8% vs 19.8%)
- Albert David's year on year earnings growth rate has been positive over the past 5 years.
- Albert David used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Albert David has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Albert David's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (66.8% vs 22.7%).
- Albert David has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Albert David's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Albert David is good value based on assets compared to the IN Pharmaceuticals industry average.
- Albert David is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Albert David is good value based on earnings compared to the India market.
- 524075 outperformed the Market in India which returned -14.5% over the past year.
- Albert David's share price is below the future cash flow value, but not at a substantial discount (< 40%).
- 524075 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- BSE:524075 is up 3.2% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524075 is up 3.2% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Asset Management Companies
Popular Stocks
Indian Indices
Sector Wise Stocks
IPO
Share Market
Best MF Schemes
Platforms
Resources
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800